BB-205 / Bright Biologics - LARVOL DELTA

The anti-tumor activity of a novel anti-Her2 and anti-c-Met bispecific antibody-drug conjugate (AACR 2025) - "Its cytotoxic potency was comparable to Trastuzumab-MMAE (T-MMAE) in Her2-high expressing cancer cells and to Telisotuzumab vedotin (Teliso-V) in c-Met-high expressing cancer cells. The novel anti-Her2/anti-c-Met bispecific ADC BB-205 demonstrates superior anti-tumor activity in preclinical studies. BB-205 shows promising therapeutic potential as a first-in-class ADC drug candidate."

Genito-urinary Cancer • Kidney Cancer • Oncology • Pancreatic Cancer • Renal Cell Carcinoma • Solid Tumor • MET